Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPL | P40238 | 4/20 | 0.78 |
| ▸ | RAB9A | P51151 | 6/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.58 |
| ▸ | NPC1 | O15118 | 5/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.58 |
| ▸ | MEN1 | O00255 | 4/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.58 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.56 |
| ▸ | KIF11 | P52732 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 5/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.54 |
| ▸ | LTA4H | P09960 | 4/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.51 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.51 |
| ▸ | RELA | Q04206 | 2/20 | 0.51 |
| ▸ | AR | P10275 | 1/20 | 0.51 |
| ▸ | GFER | P55789 | 1/20 | 0.51 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.51 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL128039 | 0.88 | MPL (1.00) | MPLRAB9AALDH1A1NPC1SMN1; SMN2 | |
| SCHEMBL19626589 | 0.83 | CYP11B2 (0.56) | MPLRAB9AALDH1A1NPC1SMN1; SMN2 | |
| SCHEMBL474206 | 0.83 | MPL (0.67) | MPLRAB9AALDH1A1NPC1SMN1; SMN2 | |
| SCHEMBL126685 | 0.82 | MPL (0.69) | MPLRAB9AALDH1A1NPC1SMN1; SMN2 | |
| SCHEMBL1800105 | 0.81 | MPL (0.68) | MPLRAB9AALDH1A1NPC1SMN1; SMN2 | |
| SCHEMBL19625427 | 0.81 | CYP11B2 (0.53) | MPLRAB9AALDH1A1NPC1SMN1; SMN2 | |
| SCHEMBL29085894 | 0.80 | RAB9A (0.65) | MPLRAB9AALDH1A1NPC1SMN1; SMN2 | |
| SCHEMBL474200 | 0.80 | MPL (0.71) | MPLRAB9AALDH1A1NPC1SMN1; SMN2 | |
| SCHEMBL18724008 | 0.80 | MPL (0.71) | MPLRAB9AALDH1A1NPC1SMN1; SMN2 | |
| SCHEMBL21301005 | 0.80 | MPL (0.71) | MPLRAB9AALDH1A1NPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2963036-B1 | 2-ACYLAMINOTHIAZOLE DERIVATIVE AND SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2019-08-28 | — | — | EP | disclosed |
| EP-2963036-B1 | 2-ACYLAMINOTHIAZOLE DERIVATIVE AND SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2019-08-28 | — | — | EP | disclosed |
| US-9562044-B2 | 2-acylaminothiazole derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2017-02-07 | — | — | US | disclosed |
| US-9562044-B2 | 2-acylaminothiazole derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2017-02-07 | — | — | US | disclosed |
| US-9474758-B2 | Thienopyrimidinedione derivatives as TRPA1 modulators | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2016-10-25 | — | — | US | disclosed |
| US-9474758-B2 | Thienopyrimidinedione derivatives as TRPA1 modulators | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2016-10-25 | — | — | US | disclosed |
| US-9474758-B2 | Thienopyrimidinedione derivatives as TRPA1 modulators | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2016-10-25 | — | — | US | disclosed |
| CN-103755720-B | Thienopyrimidine derovatives as TRPA1 regulator | 格兰马克药品股份有限公司 | 2016-07-06 | — | — | CN | disclosed |
| US-20160002218-A1 | 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2016-01-07 | — | — | US | disclosed |
| US-20160002218-A1 | 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2016-01-07 | — | — | US | disclosed |
| WO-2010109328-A1 | ISOTHIAZOLO-PYRIMIDINEDIONE DERIVATIVES AS TRPA1 MODULATORS | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2010-09-30 | — | — | WO | disclosed |
| WO-2010109328-A1 | ISOTHIAZOLO-PYRIMIDINEDIONE DERIVATIVES AS TRPA1 MODULATORS | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2010-09-30 | — | — | WO | disclosed |
| WO-2010109334-A2 | THIENOPYRIMIDINEDIONE DERIVATIVES AS TRPA1 MODULATORS | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2010-09-30 | — | — | WO | disclosed |
| WO-2010004390-A1 | QUINAZOLINE DIONE DERIVATIVES AS TRPA1 MODULATORS | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2010-01-14 | — | — | WO | disclosed |
| WO-2010004390-A1 | QUINAZOLINE DIONE DERIVATIVES AS TRPA1 MODULATORS | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2010-01-14 | — | — | WO | disclosed |
| US-20090325987-A1 | QUINAZOLINEDIONE DERIVATIVES AS TRPA1 MODULATORS | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2009-12-31 | — | — | US | disclosed |
| US-20090325987-A1 | QUINAZOLINEDIONE DERIVATIVES AS TRPA1 MODULATORS | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2009-12-31 | — | — | US | disclosed |
| US-20090325987-A1 | QUINAZOLINEDIONE DERIVATIVES AS TRPA1 MODULATORS | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2009-12-31 | — | — | US | disclosed |
| WO-2009118596-A2 | PHTHALIMIDE DERIVATIVES AS TRPA1 MODULATORS | GLENMARK PHARMACEUTICALS, S. A. (CH) | 2009-10-01 | — | — | WO | disclosed |
| WO-2009118596-A2 | PHTHALIMIDE DERIVATIVES AS TRPA1 MODULATORS | GLENMARK PHARMACEUTICALS, S. A. (CH) | 2009-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160002218-A1 | 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF | CHRM3, CHRM2, CHRM5 | MPL 3292/4885RAB9A 2669/4885ALDH1A1 1565/4885 |
| US-20090325987-A1 | QUINAZOLINEDIONE DERIVATIVES AS TRPA1 MODULATORS | TRPA1, TRPV1, TRPC3 | MPL 4421/4885RAB9A 2497/4885ALDH1A1 871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.